A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants.
Liu Y, Zhao D, Wang Y, Chen Z, Yang L, Li W, Gong Y, Gan C, Tang J, Zhang T, Tang D, Dong X, Yang Q, Valencia CA, Dai L, Qi S, Dong B, Chow HY, Li Y.
Liu Y, et al.
Front Immunol. 2022 Nov 9;13:1011484. doi: 10.3389/fimmu.2022.1011484. eCollection 2022.
Front Immunol. 2022.
PMID: 36439096
Free PMC article.